References
- Zhou Y, Barlogie B, Shaughnessy JD Jr. The molecular characterization and clinical management of multiple myeloma in the post-genome era. Leukemia 2009;23:1941–1946.
- Akiyama M, Hideshima T, Hayashi T, et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 2002;62:3876–3882.
- Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655–1657.
- Peterson TR, Laplante M, Thoreen CC, et al. DEPTOR is an mTOR inhibitor whose frequent overexpression in multiple myeloma cells promotes their survival. Cell 2009;137:873–886.
- Knobloch J, Schmitz I, Gotz K, Schulze-Osthoff K, Ruther U. Thalidomide induces limb anomalies by PTEN stabilization, Akt suppression, and stimulation of caspase-dependent cell death. Mol Cell Biol 2008;28:529–538.
- Boyd KD, Walker BA, Wardell CP, et al. High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma 2010;51:2126–2129.
- Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020–2028.
- Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2:927–937.